Your browser doesn't support javascript.
loading
Seroprevalence of hepatitis B, C, and D and associated factors in the semi-isolated Yanomami Amazonian indigenous community.
Vasconcelos, Mariana Pinheiro Alves; Sánchez-Arcila, Juan Camilo; Peres, Luciana; de Sousa, Paulo Sérgio Fonseca; Castro-Alves, Júlio; Albuquerque, Hermano Gomes; Mendes-Correa, Maria Cássia; Maia-Herzog, Marilza; Lewis-Ximenez, Lia Laura; Villar, Lívia Melo; Oliveira-Ferreira, Joseli.
Afiliação
  • Vasconcelos MPA; Centro de Medicina Tropical de Rondônia - CEMETRON, Porto Velho, Rondônia, Brazil.
  • Sánchez-Arcila JC; Laboratório de Imunoparasitologia do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Rio de Janeiro, Brazil.
  • Peres L; Laboratório de Imunoparasitologia do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Rio de Janeiro, Brazil.
  • de Sousa PSF; Laboratório de Hepatites Virais do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Brazil.
  • Castro-Alves J; Laboratório de Hepatites Virais do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Brazil.
  • Albuquerque HG; Instituto Nacional de Infectologia Evandro Chagas da Fundação Oswaldo Cruz - FIOCRUZ, Rio de Janeiro, Brazil.
  • Mendes-Correa MC; Laboratório de Doenças Parasitárias do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Brazil.
  • Maia-Herzog M; Departamento de Moléstias Infecciosas e Parasitárias da Faculdade de Medicina da Universidade de São Paulo - USP, São Paulo, Brazil.
  • Lewis-Ximenez LL; Laboratório de Referência Nacional em Simulídeos, Oncocercose e Mansonelose, Coleção de Simulídeos do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Brazil.
  • Villar LM; Laboratório de Hepatites Virais do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Brazil.
  • Oliveira-Ferreira J; Laboratório de Hepatites Virais do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Brazil.
BMC Infect Dis ; 24(1): 15, 2024 Jan 02.
Article em En | MEDLINE | ID: mdl-38166687
ABSTRACT

BACKGROUND:

Viral hepatitis is a significant health concern among indigenous population in the Americas. In Brazil, reports find high endemicity of HBV and HDV infections has been reported in several indigenous groups. However, few studies have documented the prevalence of HBV, HCV and HDV in the Yanomami. In this study, the prevalence of hepatitis B, C, and D serological markers and potential risk factors were investigated to provide guidance for the development of strategies aimed at reducing viral transmission in the Yanomami indigenous villages.

METHODS:

This cross-sectional study was carried out in March 2015 and included 430 individuals from four Yanomami villages Alapusi (n = 78), Castanha/Ahima (n = 126), Gasolina (n = 105), and Taibrapa (n = 121). A rapid test was used for detection of HBsAg and anti-HCV and chemiluminescent immunoassay for anti-HBs, anti-HBc, and anti-HDV antibodies.

RESULTS:

HBsAg, anti-HBc, and anti-HBs were detected in 8.8, 45.5, and 49.4% of the participants, respectively. The estimated HBV status current infection 9.6% (38/395); resolved infection 43.3% (171/395); vaccine immunity 20.5% (81/395), and susceptible to HBV 26.6% (105/395). Gasolina presented the lowest prevalence of HBV infection (6.5%) and the highest prevalence of vaccine immunity (26.9%). Children < 15 years old were highly susceptible to infection, as 53.1% did not have antibodies to HBV, while more than 80% of individuals over 45 years of age had been exposed to HBV. The markers for HDV were founded among 12.5% (4/32) of the HBsAg carriers. Anti-HCV was identified in all villages, with the highest prevalence in Alapusi (5.1%). Possible risk factors such as the use of piercings, tattoos, and contact with prospectors showed no statistical difference between the groups.

CONCLUSIONS:

Viral hepatitis B and serological markers for HCV and HDV were found to be widely distributed among the Yanomami indigenous community, while the prevalence of vaccine immunity to HBV was low. This finding reinforces the importance of promoting systematized diagnostic and vaccination strategies in indigenous communities. Our data confirm that isolated and difficult-to-reach indigenous communities lack appropriate access to diagnosis, treatment, and vaccination.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Hepatite C / Hepatite B / Hepatite Viral Humana Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Humans Idioma: En Revista: BMC Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Hepatite C / Hepatite B / Hepatite Viral Humana Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Humans Idioma: En Revista: BMC Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido